Bill would extend ALS research grant law through 2031
Passed both chambersH.R. 8205Latest action
Sponsor: Mike Quigley · Representative · IL
AIDecoded by AI · checked against the recordRead the official text
Official title: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
119th Congress
Topics: Health care
Introduced:
Read the official bill on Congress.govIn plain words
The plain-language version comes first. The official text is always the reference.
HR 8205 extends ALS research grant funding authority from 2026 to 2031 and adds FDA oversight steps.
45-second read · 4 questions answered below
What does this do?
This bill extends the Accelerating Access to Critical Therapies for ALS Act, pushing its expiration from 2026 to 2031 so grant programs for ALS research can continue. It adds requirements for the FDA to check clinical trial progress, including interim data, when companies renew grants, and clarifies that "phase 3" trials include combined phase 2/3 and planned-but-not-yet-enrolling trials. It also requires an updated FDA action plan within a year and a review within four years.
Who does it affect?
The bill affects ALS patients and families, pharmaceutical and biotech companies developing ALS treatments, and researchers using federal grants. The FDA gains added reporting and oversight duties.
Why does it matter?
The extension keeps existing grant funding authority active rather than letting it lapse in 2026, while adding new FDA data-sharing and reporting requirements that increase oversight of grant recipients.
AI-drafted summary. Check it against the official text before you act on it.
Read the official bill on Congress.govMake the call
Where does it stand?
- IntroducedApr 6, 2026
- House committee
- House vote
- Senate
- The president's deskYou are here · Oct 14, 2026
Right now: both chambers have passed it. It goes to the president next.
Latest action: — Message on Senate action sent to the House.